PepGen (PEPG) Accumulated Depreciation (2021 - 2026)
PepGen (PEPG) posted Accumulated Depreciation of $4.2 million for Q1 2026, up 8.13% sequentially from $3.9 million in Q4 2025, and up 23.4% YoY from $3.4 million in Q1 2025.
Analysis
PepGen (PEPG) Accumulated Depreciation (2021 - 2026) Analysis & Trends
PepGen has reported Accumulated Depreciation for 6 years, with the latest figure at $4.2 million in Q1 2026.
- Quarterly Accumulated Depreciation rose 23.4% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (up 23.4% YoY) and the FY2025 annual result came in at $3.9 million, up 28.4% from the prior year.
- Accumulated Depreciation improved to $4.2 million in Q1 2026 per PEPG's latest filing, from $3.9 million in the prior quarter.
- Over five years, Accumulated Depreciation peaked at $4.2 million in Q1 2026 and troughed at $245000.0 in Q3 2022.
- A 5-year average of $2.0 million and a median of $1.9 million in 2024 frame the typical range for Accumulated Depreciation.
- The sharpest annual moves came in 2022 and 2023: Accumulated Depreciation declined 9.53% in 2022, then jumped 397.96% in 2023.
- Over 5 years, Accumulated Depreciation stood at $389000.0 in 2022, then surged by 304.11% to $1.6 million in 2023, then surged by 93.77% to $3.0 million in 2024, then climbed by 28.4% to $3.9 million in 2025, then grew by 8.13% to $4.2 million in 2026.
- According to Business Quant data, Accumulated Depreciation over the past three periods registered $4.2 million, $3.9 million, and $3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.48 Mn |
| Mar 31, 2026 | 4.23 Mn |
| Dec 31, 2025 | 3.91 Mn |
| Sep 30, 2025 | 3.58 Mn |
| Jun 30, 2025 | 3.24 Mn |
| Mar 31, 2025 | 3.43 Mn |
| Dec 31, 2024 | 3.05 Mn |
| Sep 30, 2024 | 2.69 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Mar 31, 2024 | 1.94 Mn |
| Dec 31, 2023 | 1.57 Mn |
| Sep 30, 2023 | 1.22 Mn |
| Jun 30, 2023 | 871,000.00 |
| Mar 31, 2023 | 540,000.00 |
| Dec 31, 2022 | 389,000.00 |
| Sep 30, 2022 | 245,000.00 |
| Jun 30, 2022 | 415,000.00 |
| Mar 31, 2022 | 471,000.00 |
| Dec 31, 2021 | 430,000.00 |